EHEija Heikkilä

Eija Heikkilä

*This is an algorithmically generated author record based on publicly available information.

Eija Heikkilä has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland

    by Aija Knuuttila, Monica H. Ekblom, Lalli O. Nurmi, Anna Bonin, Eija K. Heikkilä, Maria Silvoniemi

    Background and purpose: The aim of the study was to compare overall survival (OS) and time to next treatment (TTNT) of epidermal growth factor receptor (EGFR) mutation positive Non-Small Cell Lung Cancer (NSCLC) patients from start of first therapy, by EGFR mutational sub-type, disease stage at first diagnosis (early vs. advanced stage), first treatment and metastatic sites. Patient/material and methods: This retrospective observational study utilized patient-level data from hospital data lakes at two university hospital districts in Southern Finland on EGFR-mutation-positive NSCLC patients diagnosed between 2017 and 2023. OS and TTNT were analysed from start of first therapy using Kaplan–Meier, multivariable Cox proportional hazard models and log-rank test. Results: Among 544 EGFR-mutant NSCLC patients, 42% had early-stage disease. In early-stage NSCLC, OS did not differ significantly between Del19 and L858R mutations, and surgery was the only initial treatment associated with improved OS, with Del19 providing no additional survival benefit. In advanced-stage NSCLC, L858R mutation was a risk factor for shorter OS compared to Del19 (hazard ratio [HR]: 2.01 95% confidence interval [CI]: 1.34–3.02, p = 0.001). First-line third-generation tyrosine kinase inhibitor (TKI) showed improved OS compared to first-generation TKI (HR: 0.46 95% CI: 0.28–0.78, p = 0.004). Younger patients more often had central nervous system (CNS) and bone metastases. CNS and liver metastases at diagnosis were linked to shorter OS (5.0 and 8.1 months, respectively). Interpretation: EGFR subtype did not affect outcomes in early-stage NSCLC, while Del19 mutations and first-line third-generation TKIs were associated with better outcomes in advanced disease. Younger patients had higher rates of CNS and bone metastases, which were associated with shorter OS.

  • Open Access

    Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland

    by Atte Vaden, Mari Lahelma, Lalli Nurmi, Eija Heikkilä, Hannu Vessari, Hanne Luoto, Tero Saukkonen, Leo Niskanen

    Aim: This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland. Materials and Methods: Adults living with T2D ( n = 7249) who initiated oral semaglutide between April 1, 2021, and December 31, 2023, were identified from national registers and followed until June 30, 2024. Primary endpoints were changes in HbA1c and body weight from baseline to 182.5 and 365 days. Secondary endpoints included changes in LDL‐cholesterol, HDL‐cholesterol, total cholesterol, triglycerides, HDL/triglycerides ratio, and ALT. Results: Of those initiating oral semaglutide, 65.8% remained on treatment at 180 days and 55.2% at 365 days. Among patients included in longitudinal trajectory modelling, mean HbA1c ( n = 2784) decreased from 7.9% to 6.8% at 182.5 days (95% CI: −1.20 to −1.04; p < 0.001) and to 6.9% at 365 days (95% CI: −1.18 to −0.95; p < 0.001). Mean body weight ( n = 832) declined from 106 to 100 kg at 182.5 days (95% CI: −7 to −5; p < 0.001) and to 98 kg at 365 days (95% CI: −10 to −6; p < 0.001). LDL‐cholesterol ( n = 1402), and triglycerides ( n = 975) were significantly reduced at 182.5 days with little further change at 365 days. Mean ALT ( n = 1762) declined from 50 to 42 U/L at 182.5 days (95% CI: −10 to −6, p < 0.001) and to 37 U/L at 365 days (; 95% CI: −16 to −10; p < 0.001). While weight at baseline was lower at patients aged at least 75 years, the changes in HbA1c and weight were similar compared to patients under 75 years of age. Conclusion: Oral semaglutide significantly improves glycaemic and lipid control, body weight, and liver enzymes in adults living with T2D treated in clinical practice.


  • Open Access

    FIN-EGFRprint: a Finnish real-world study on treatments and outcomes in advanced NSCLC with common EGFR mutations

    by Aija Knuuttila, Lalli O Nurmi, Petri M Vänni, Eija K Heikkilä, Joanne Edwards, Monica H Ekblom, Irene Luccarini, Maria Silvoniemi

    Background and purpose: The treatment of advanced non-small cell lung cancer (aNSCLC) with common epidermal growth factor receptor (cEGFR) mutations has evolved substantially over the last 15 years, with the discovery of activating epidermal growth factor receptor (EGFR) mutations and introduction of first-, second- and third generation (gen) EGFR tyrosine kinase inhibitors (TKIs) as first-line therapy. This retrospective observational study aimed to evaluate whether the introduction of these treatments has led to improved ‘real-world’ outcomes over time by analysing time to next treatment (TTNT) and overall survival (OS). Patient/material and methods: Patients (n = 379) with EGFR exon 19 deletion (Del19) or exon 21 L858R (L858R) substitution and aNSCLC were identified from two Finnish university hospital data lakes between 2010 and 2023. TTNT and OS were analysed from first-line treatment initiation using Kaplan–Meier survival and multivariable Cox regression analyses. Patients were stratified into three cohorts based on date of diagnosis and which TKIs were available at that time (1st-gen: 2010–2016, 2nd-gen: 2017–2020 and 3rd-gen: 2020–2023). Results: The use of chemotherapy as first-line therapy declined from 32% (2010–2016) to 6% (2020–2023), while 80% of patients received 3rd-gen TKIs as first-line treatment in 2020–2023. Median TTNT improved over time (9.7 to 13.2 to 21.6), with a significant improvement in 2020–2023 versus 2010–2016 (HR: 0.46; 95% CI: 0.33–0.64; p < 0.001). Median OS also increased over time (19.1 to 23.9 to 29.3 months) and was significantly higher in 2020–2023 versus 2010–2016 (HR: 0.56; 95% CI: 0.39–0.82; p = 0.002). Interpretation: ‘Real-world’ treatment outcomes for aNSCLC with cEGFR mutations have improved over time likely due to the transition from 1st- to 3rd-gen TKIs. However, real-word survival with TKIs remains lower than clinical trials results emphasizing the unmet need.


  • Open Access

    A systematic review and meta-analysis of lung cancer risk prediction models

    by Ghida Khalife, Matilda Nilsson, Lotta Peltola, Juho Waris, Antti Jekunen, Riikka-Leena Leskelä, Heidi Andersén, Mikko Nuutinen, Eija Heikkilä, Susanna Nurmi-Rantala, et al.

    Background: Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. Early detection through targeted screening significantly improves patient outcomes. However, identifying high-risk individuals remains a critical challenge. Purpose: This systematic review evaluates externally validated LC risk prediction models to assess their performance and potential applicability in screening strategies. Methods: Of the 11,805 initial studies, 66 met inclusion criteria and 38 published mainly between 2020 and 2024 were included in the final analysis. Model methodologies, validation approaches, and performance metrics were extracted and compared. Results: The review identified 18 models utilising conventional machine learning, six employing neural networks, and 14 comparing different predictive frameworks. The Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCOm2012) demonstrated superior sensitivity across diverse populations, while newer models, such as Optimized Early Warning model for Lung cancer risk (OWL) and CanPredict, showed promising results. However, differences in population demographics and healthcare systems may limit the generalisability of these models. Interpretation: While LC risk prediction models have advanced, their applicability to specific healthcare systems, such as Finland’s, requires further adaptation and validation. Future research should focus on optimising these models for local contexts to improve clinical impact and cost-effectiveness in targeted screening programmes. Systematic review registration: PROSPERO CRD42022321391.


  • Open Access

    Cost comparison analysis of continuous versus intermittent antimicrobial therapy infusions in inpatient and outpatient care: real-world data from Finland

    by Tuukka Hakkarainen, Mari Lahelma, Terhi Rahkonen, Ville Lehtinen, Julian Shepelev, Trine Gram, Eija Heikkila

    Objective This study compared the costs and nursing time associated with the delivery of continuous infusion of antibiotics via elastomeric infusion pumps (EIP) versus conventional intermittent infusion (CII) across different care pathways. Design Retrospective real-world data informed a cost comparison analysis that compared costs and nursing hours between infusion of antibiotics via EIP versus CII across eight care pathways in inpatient or outpatient care during infection episodes. Real-world data were obtained from patients treated within a year with parenteral antimicrobial therapy in Päijät-Häme Region, Finland. Setting Inpatient care with hospital admission and outpatient care at hospital at home in Päijät-Häme Region in Finland. Participants 3778 patients with a total of 4214 infection episodes treated with intravenous antimicrobial therapy. Interventions Eight treatment strategies with various combinations of EIP and CII administered in inpatient or outpatient care. Primary and secondary outcome measures Direct costs and nursing time. Results Skin and soft tissue infections accounted for the highest number of episodes treated with EIP overall (30.8%; 74 out of 240 episodes) and in outpatient care specifically (53.3%; 128 out of 240 episodes). Compared with inpatient care costs with CII (€4590 per episode), treating skin and soft tissue infections in outpatient care with EIP or CII incurred only 24% (€1104) and 35% (€1620) of the costs, respectively. Across all treatment strategies and infections studied, the use of EIP consistently required less nursing time. The highest nursing time in the outpatient care was observed in sepsis episodes treated with CII (37 hours with CII vs 7 hours with EIP per episode). Conclusion Delivery of antimicrobial therapy using continuous infusions with EIP instead of CII can significantly decrease the nursing time and cost in both inpatient and outpatient care. For skin and soft tissue infections and sepsis, the utilisation of EIP is a cost-saving option in outpatient care compared with the use of CII.


  • Open Access

    Effectiveness of Telemonitoring in Reducing Hospitalization and Associated Costs for Patients With Heart Failure in Finland: Nonrandomized Pre-Post Telemonitoring Study

    by Jorma Kokkonen, Pirjo Mustonen, Eija Heikkilä, Riikka-Leena Leskelä, Paula Pennanen, Kati Krühn, Arto Jalkanen, Jussi-Pekka Laakso, Jari Kempers, Sami Väisänen, et al.

    Background: Many patients with chronic heart failure (HF) experience a reduced health status, leading to readmission after hospitalization despite receiving conventional care. Telemonitoring approaches aim to improve the early detection of HF decompensations and prevent readmissions. However, knowledge about the impact of telemonitoring on preventing readmissions and related costs remains scarce. Objective: This study assessed the effectiveness of adding a telemonitoring solution to the standard of care (SOC) for the prevention of hospitalization and related costs in patients with HF in Finland. Methods: We performed a nonrandomized pre-post telemonitoring study to estimate health care costs and resource use during 6 months on SOC followed by 6 months on SOC with a novel telemonitoring solution. The telemonitoring solution consisted of a digital platform for patient-reported symptoms and daily weight and blood pressure measurements, automatically generated alerts triggering phone calls with secondary care nurses, and rapid response to alerts by treating physicians. Telemonitoring solution data were linked to patient register data on primary care, secondary care, and hospitalization. The patient register of the Southern Savonia Social and Health Care Authority (Essote) was used. Eligible patients had at least 1 hospital admission within the last 12 months and self-reported New York Heart Association class II-IV from the central hospital in the Southern Savonia region. Results: Out of 50 recruited patients with HF, 43 completed the study and were included in the analysis. The hospitalization-related cost decreased (49%; P=.03) from €2189 (95% CI €1384-€2994; a currency exchange rate of EUR €1=US $1.10589 is applicable) during SOC to €1114 (95% CI €425-€1803) during telemonitoring. The number of patients with at least 1 hospitalization due to HF was reduced by 70% (P=.002) from 20 (47%) out of 43patients during SOC to 6 (14%) out of 43 patients in telemonitoring. The estimated mean total health care cost per patient was €3124 (95% CI €2212-€4036) during SOC and €2104 (95% CI €1313-€2895) during telemonitoring, resulting in a 33% reduction (P=.07) in costs with telemonitoring. Conclusions: The results suggest that the telemonitoring solution can reduce hospital-related costs for patients with HF with a recent hospital admission.


  • Open Access

    Effectiveness of Telemonitoring in Reducing Hospitalization and Associated Costs for Patients With Heart Failure in Finland: Nonrandomized Pre-Post Telemonitoring Study (Preprint)

    by Jorma Kokkonen, Pirjo Mustonen, Eija Heikkilä, Riikka-Leena Leskelä, Paula Pennanen, Kati Krühn, Arto Jalkanen, Jussi-Pekka Laakso, Jari Kempers, Sami Väisänen, et al.

    BACKGROUND Many patients with chronic heart failure (HF) experience a reduced health status, leading to readmission after hospitalization despite receiving conventional care. Telemonitoring approaches aim to improve the early detection of HF decompensations and prevent readmissions. However, knowledge about the impact of telemonitoring on preventing readmissions and related costs remains scarce. OBJECTIVE This study assessed the effectiveness of adding a telemonitoring solution to the standard of care (SOC) for the prevention of hospitalization and related costs in patients with HF in Finland. METHODS We performed a nonrandomized pre-post telemonitoring study to estimate health care costs and resource use during 6 months on SOC followed by 6 months on SOC with a novel telemonitoring solution. The telemonitoring solution consisted of a digital platform for patient-reported symptoms and daily weight and blood pressure measurements, automatically generated alerts triggering phone calls with secondary care nurses, and rapid response to alerts by treating physicians. Telemonitoring solution data were linked to patient register data on primary care, secondary care, and hospitalization. The patient register of the Southern Savonia Social and Health Care Authority (Essote) was used. Eligible patients had at least 1 hospital admission within the last 12 months and self-reported New York Heart Association class II-IV from the central hospital in the Southern Savonia region. RESULTS Out of 50 recruited patients with HF, 43 completed the study and were included in the analysis. The hospitalization-related cost decreased (49%; P=.03) from €2189 (95% CI €1384-€2994; a currency exchange rate of EUR €1=US $1.10589 is applicable) during SOC to €1114 (95% CI €425-€1803) during telemonitoring. The number of patients with at least 1 hospitalization due to HF was reduced by 70% (P=.002) from 20 (47%) out of 43patients during SOC to 6 (14%) out of 43 patients in telemonitoring. The estimated mean total health care cost per patient was €3124 (95% CI €2212-€4036) during SOC and €2104 (95% CI €1313-€2895) during telemonitoring, resulting in a 33% reduction (P=.07) in costs with telemonitoring. CONCLUSIONS The results suggest that the telemonitoring solution can reduce hospital-related costs for patients with HF with a recent hospital admission.